Dr. Fred Schumacher is Associate Professor in the Department of Population and Quantitative Health Sciences and Faculty in the Cleveland Institute for Computational Biology, both at Case Western Reserve University. Dr. Schumacher is also Co-Leader of the Cancer Prevention Control & Population Research Program as part of the Case Comprehensive Cancer Center. His primary research focus is on cancer, particularly prostate cancer. As an investigator and leader in several major international consortium, Dr. Schumacher has
- Identified multiple novel genomic regions associated with prostate, testicular and breast cancer, representing discoveries based on incorporating genome-wide association studies (GWAS) with cancer epidemiology
- Expanded the use of GWAS through combined studies of varying design, providing the power to evaluate candidate gene pathways, incorporate related biomarkers, and assess cancer sub-types
- Explored the potential biological overlap of complex traits and conditions (such as diabetes) with cancer, providing a better understanding of the cancer initiation process and highlighting several areas for potential disease risk reduction.
- Developed and implemented polygenic risk scores to improve screening modalities and treatment paradigms
- Isali, I, Wong, TR, Batur, AF, Wu, CW, Schumacher, FR, Pope, R, Hijaz, A, Sheyn, D. Recurrent urinary tract infection genetic risk: a systematic review and gene network analysis. Int Urogynecol J 2023; : . PubMed PMID:37917182 .
- Meng, G, Pan, Y, Tang, W, Zhang, L, Cui, Y, Schumacher, FR, Wang, M, Wang, R, He, S, Krischer, J et al.. imply: improving cell-type deconvolution accuracy using personalized reference profiles. bioRxiv 2023; : . PubMed PMID:37808714 PubMed Central PMC10557724.
- Thomas, M, Su, YR, Rosenthal, EA, Sakoda, LC, Schmit, SL, Timofeeva, MN, Chen, Z, Fernandez-Rozadilla, C, Law, PJ, Murphy, N et al.. Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations. Nat Commun 2023; 14 (1): 6147. PubMed PMID:37783704 PubMed Central PMC10545678.
- Wu, CW, Badreddine, J, Chang, J, Huang, YM, Kim, FJ, Wild, T, Tsai, AC, Meeks, N, Donalisio Da Silva, R, Molina, WR et al.. Population genetics analysis of SLC3A1 and SLC7A9 revealed the etiology of cystine stone may be more than what our current genetic knowledge can explain. Urolithiasis 2023; 51 (1): 101. PubMed PMID:37561200 .
- Booker, BD, Markt, SC, Schumacher, FR, Rose, J, Cooper, G, Selfridge, JE, Koroukian, SM. Variation in KRAS/NRAS/BRAF-Mutation Status by Age, Sex, and Race/Ethnicity Among a Large Cohort of Patients with Metastatic Colorectal Cancer (mCRC). J Gastrointest Cancer 2023; : . PubMed PMID:37355486 .
- Arenas-Gallo, C, Rhodes, S, Garcia, JA, Weinstein, I, Prunty, M, Lewicki, P, Brant, A, Basourakos, SP, Barbieri, CE, Lifschutz, N et al.. Prostate cancer genetic alterations in Hispanic men. Prostate 2023; 83 (13): 1263-1269. PubMed PMID:37301735 .
- Yarmolinsky, J, Bouras, E, Constantinescu, A, Burrows, K, Bull, CJ, Vincent, EE, Martin, RM, Dimopoulou, O, Lewis, SJ, Moreno, V et al.. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis. Diabetologia 2023; 66 (8): 1481-1500. PubMed PMID:37171501 PubMed Central PMC10317892.
- Shu, TD, Schumacher, FR, Conroy, B, Ponsky, L, Mahran, A, Bukavina, L, Calaway, A, Markt, SC. Disparities in cause-specific mortality by race and sex among bladder cancer patients from the SEER database. Cancer Causes Control 2023; 34 (6): 521-531. PubMed PMID:36882598 .
- Thomas, M, Su, YR, Rosenthal, EA, Sakoda, LC, Schmit, SL, Timofeeva, MN, Chen, Z, Fernandez-Rozadilla, C, Law, PJ, Murphy, N et al.. Combining Asian-European Genome-Wide Association Studies of Colorectal Cancer Improves Risk Prediction Across Race and Ethnicity. medRxiv 2023; : . PubMed PMID:36789420 PubMed Central PMC9928144.
- Koroukian, SM, Booker, BD, Vu, L, Schumacher, FR, Rose, J, Cooper, GS, Selfridge, JE, Markt, SC. Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer. JAMA Netw Open 2023; 6 (1): e2250030. PubMed PMID:36656585 PubMed Central PMC9857024.